Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | LSS | P48449 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 5/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8507191 | 0.79 | CYP1A2 (0.56) | CYP1A2LSSDPP4POLBHPGD | |
| Fluoride SCHEMBL30330840 | 0.77 | CYP1A2 (0.54) | CYP1A2LSSDPP4POLBHPGD | |
| SCHEMBL772799 | 0.77 | — | — | |
| SCHEMBL4988747 | 0.76 | LSS (0.48) | CYP1A2LSSPOLBMAPTMEN1 | |
| SCHEMBL12561561 | 0.76 | CYP1A2 (0.52) | CYP1A2LSSDPP4BCHE | |
| SCHEMBL13570070 | 0.75 | CYP1A2 (0.43) | CYP1A2LSSMEN1KMT2AHRH3 | |
| Hydrochloric Acid SCHEMBL30330784 | 0.74 | CYP1A2 (0.50) | CYP1A2LSSBCHE | |
| Cyanide SCHEMBL30330797 | 0.74 | CYP1A2 (0.50) | CYP1A2LSSDPP4POLBHPGD | |
| Methoxymethane SCHEMBL8030839 | 0.73 | CYP1A2 (0.81) | CYP1A2POLBHPGDMAPTLMNA | |
| SCHEMBL19454711 | 0.73 | LSS (0.51) | CYP1A2LSSHRH3BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573915-B2 | Ionic liquids, the method for preparing the same and method for removing acetylenes from olefin mixtures using the ionic liquids | KOLON INDUSTRIES, INC. (KR) | 2017-02-21 | — | — | US | disclosed |
| US-20140296523-A1 | Ionic Liquids, The Method For Preparing The Same And Method For Removing Acetylenes From Olefin Mixtures Using The Ionic Liquids | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2014-10-02 | — | — | US | disclosed |
| US-8785711-B2 | Ionic liquids, the method for preparing the same and method for removing acetylenes from olefin mixtures using the ionic liquids | KOLON INDUSTRIES, INC. (KR) | 2014-07-22 | — | — | US | disclosed |
| US-20120083642-A1 | IONIC LIQUIDS, THE METHOD FOR PREPARING THE SAME AND METHOD FOR REMOVING ACETYLENES FROM OLEFIN MIXTURES USING THE IONIC LIQUIDS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083642-A1 | IONIC LIQUIDS, THE METHOD FOR PREPARING THE SAME AND METHOD FOR REMOVING ACETYLENES FROM OLEFIN MIXTURES USING THE IONIC LIQUIDS | AOX1, ACOX1, AOC2 | CYP1A2 154/4885LSS 1489/4885DPP4 4757/4885 |
| US-20140296523-A1 | Ionic Liquids, The Method For Preparing The Same And Method For Removing Acetylenes From Olefin Mixtures Using The Ionic Liquids | AOX1, ACOX1, AOC2 | CYP1A2 154/4885LSS 1489/4885DPP4 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.